The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, MyelomaAugust 30, 2022
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, MyelomaJuly 28, 2022
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, MyelomaOctober 19, 2021
Research Grant Application – Shared-Decision Making in MyelomaMPE, Myeloma, Patient evidenceOctober 11, 2021
